Zentalis Pharmaceuticals, Inc. (ZNTL)
| Market Cap | 2.08B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -117.84M |
| Shares Out | 41.04M |
| EPS (ttm) | -4.19 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 16 |
| Last Price | $50.68 |
| Previous Close | $50.28 |
| Change ($) | 0.40 |
| Change (%) | 0.80% |
| Day's Open | 50.61 |
| Day's Range | 48.01 - 52.50 |
| Day's Volume | 331,137 |
| 52-Week Range | 23.50 - 61.29 |
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) has announced initial efficacy and safety data from the Phase 1 dose-escalation portion of its ongoing Phase 1/2 trial evaluating ZN-c3 in patients with advan...
ZN-c3 is currently being evaluated in patients with advanced solid tumors and ovarian cancer ZN-c3 is currently being evaluated in patients with advanced solid tumors and ovarian cancer
ZN-c3 demonstrated single agent activity, generating Exceptional Responses in a range of heavily pre-treated solid tumors
Initiated multiple early-stage clinical trials evaluating its oral SERD, ZN-c5, WEE1 inhibitor, ZN-c3 and BCL-2 inhibitor, ZN-d5
Additional preclinical data on ZN-c3 and the Company's EGFR inhibitor, ZN-e4, will be presented as poster presentations Additional preclinical data on ZN-c3 and the Company's EGFR inhibitor, ZN-e4, will...
NEW YORK and SAN DIEGO, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule t...
NEW YORK & SAN DIEGO, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule the...
NEW YORK and SAN DIEGO, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule t...
Zentalis (ZNTL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Andreas Halvorsen (Trades, Portfolio) has revealed a reduction in his holding of Zentalis Pharmaceuticals Inc. (NASDAQ:ZNTL), according to GuruFocus' Real-Time Picks, a Premium feature.
NEW YORK and SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule t...
Live webcast to be held on September 24th at 12:00 p.m. EDT Live webcast to be held on September 24th at 12:00 p.m. EDT
NEW YORK and SAN DIEGO, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecul...
Closed initial public offering (IPO) of common stock, raising gross proceeds of ~$190.0 million Raised an additional ~$144.4 million in gross proceeds from recent follow-on offering Completed a $20....
NEW YORK and SAN DIEGO, July 29, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule...
NEW YORK and SAN DIEGO, July 27, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule...
NEW YORK & SAN DIEGO, July 27, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule t...
NEW YORK and SAN DIEGO, July 01, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule...
Health care companies and governments are racing to find a vaccine or other effective treatment for Covid-19 -- so investors have been piling into stocks like Gilead Sciences, Moderna and Novavax.
NEW YORK and SAN DIEGO, June 15, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule...
The company's share price has nearly tripled since its IPO less than two months ago. Is it too late to get in on the fun?
NEW YORK, SAN DIEGO and DURHAM, N.C., May 28, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) and Tavros Therapeutics, Inc., today announced a strategic collaboration to apply T...
Zentera will be the sole licensee of three Zentalis discovered therapies for development and commercialization in China Zentera will be the sole licensee of three Zentalis discovered therapies for devel...
Zentera will be the sole licensee of three Zentalis discovered therapies for development and commercialization in China Zentera will be the sole licensee of three Zentalis discovered therapies for devel...
Completed initial public offering of common stock, raising approximately $190.0 million in gross proceeds
ZN-d5 is the Company’s fourth product candidate to receive IND clearance in five years ZN-d5 is the Company’s fourth product candidate to receive IND clearance in five years
These companies just raised significant cash to advance promising drug pipelines.
Biotech pharmaceutical company Zentalis Pharmaceuticals has launched a successful IPO that values the company at over $730 million.
About ZNTL
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidates are the ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer; and ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 1/2 clinical tri... [Read more...]
| Industry Biotechnology | IPO Date Apr 3, 2020 |
| Stock Exchange NASDAQ | Ticker Symbol ZNTL |
Analyst Forecasts
According to 5 analysts, the average rating for ZNTL stock is "Strong Buy." The 12-month stock price forecast is 66.50, which is an increase of 31.22% from the latest price.